In patients requiring VTE prophylaxis with significant immobility, which anticoagulant demonstration is supported by the MAGELLAN trial findings?

The MAGELLAN trial specifically evaluated the efficacy and safety of rivaroxaban for the prevention of venous thromboembolism (VTE) in patients who are hospitalized and have significant immobility due to an acute medical illness. The results indicated that rivaroxaban at the dose of 10 mg daily is effective in reducing the incidence of VTE in this patient population.

Rivaroxaban, a direct factor Xa inhibitor, was demonstrated to be beneficial due to its favorable pharmacokinetic profile, allowing once-daily dosing and eliminating the need for routine monitoring, which is a significant advantage for patients with limited mobility.

In contrast, the other anticoagulants listed in the choices either do not have strong support from the MAGELLAN trial data or are not typically used for this specific indication in the context of significant immobility associated with acute medical conditions. This underscores the role of rivaroxaban as an appropriate choice for VTE prophylaxis in the specified scenario.